INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$4.10
+0.07 (+1.61%)
Open$3.96
Previous Close$4.04
Day High$4.15
Day Low$3.93
52W High$43.50
52W Low$3.51
Volume—
Avg Volume60.9K
Market Cap11.08M
P/E Ratio—
EPS$-7.18
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+802.4% upside
Current
$4.10
$4.10
Target
$37.00
$37.00
$31.85
$37.00 avg
$43.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |
| Rev Growth | +8.4% | -9.6% | +19.4% |
| Debt/Equity | 0.32 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |